{'fraction_non_alphanumeric': 0.02314445331205108, 'fraction_numerical': 0.012769353551476457, 'mean_word_length': 5.6, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Patchy Speckled Bath PUVA Pigmentation

with raised alkaline phosphatase (18 KA units, normal range 4-13). Plasma calcium was 2.2 mM/I. A clinical diagnosis of osteomalacia resulting from hypophosphataemia was confirmed by marrow trephine, which showed significantly increased osteoid. Treatment was started using oral phosphate supplements and calcium with vitamin D, as shown in Figure 1, which outlines subsequent changes in bone biochemistry. Bone pain improved following correction of plasma phosphate, but a bone trephine demonstrated persisting osteomalacia. In 1991, intercurrent illness lead to cessation of all treatment. This was followed by a rapid return of hypophosphataemia with hyperphosphaturia and provided the opportunity for studies of the acute response to phosphate supplementation (Figure 2). Normal plasma concentrations of calcium and phosphate, together with reduced urinary excretion of hydroxyproline and calcium, resulted from use of a combination of phosphate and bendrofluazide therapy. On this medication the patient remains well, with no further bone pain, normal bone biochemistry and elevated but stable plasma creatinine (173 AIM). There has been no clinical or immunological evidence of progression to overt myeloma.